Industry Roundup: Pfizer Earnings, Tylenol Litigation, FTC Enforcement
This article was originally published in The Tan Sheet
Executive Summary
Nexium drives Pfizer US consumer sales; mistrial in Children’s Tylenol litigation; settlements in weight loss marketing scams; and more consumer health product industry news in brief.
You may also be interested in...
Pfizer Consumer Health True To Form Pending Move To JV With GSK
Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.
Pfizer Consumer Health True To Form Pending Move To JV With GSK
Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.
Ad Firm Behind Bogus Weight Loss Claims Fined $2M: Health And Wellness Industry News
FTC and Maine would collect $2m under a settlement on complaint that Marketing Architects created ads for a weight loss supplement firm already targeted by FTC for false claims; Long Life Unlimited warned on claims; and UK catalog claims healing powers for meristem.